Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2014

Open Access 01-12-2014 | Original research

Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

Authors: Idris Bahce, Marc C Huisman, Eline E Verwer, Rogier Ooijevaar, Firdaouss Boutkourt, Danielle J Vugts, Guus AMS van Dongen, Ronald Boellaard, Egbert F Smit

Published in: EJNMMI Research | Issue 1/2014

Login to get access

Abstract

Background

The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored.

Methods

Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak).

Results

Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS.

Conclusions

This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted.
Appendix
Available only for authorised users
Literature
1.
Okines AFC, Reynolds AR, Cunningham D: Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist 2011, 16: 844–858. 10.1634/theoncologist.2010-0387PubMedCentralCrossRefPubMed
2.
Burger RA: Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011, 121: 230–238. 10.1016/j.ygyno.2010.11.035CrossRefPubMed
3.
4.
5.
Maharaj ASR, Saint-Geniez M, Maldonado AE, D’Amore PA: Vascular endothelial growth factor localization in the adult. Am J Pathol 2006, 168: 639–648. 10.2353/ajpath.2006.050834PubMedCentralCrossRefPubMed
6.
Wu FTH, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS: A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010, 14: 528–552.PubMedCentralPubMed
7.
Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML: Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130: 691–703. 10.1016/j.cell.2007.06.054PubMedCentralCrossRefPubMed
8.
D’Amore PA: Vascular endothelial cell growth factor-A: not just for endothelial cells anymore. Am J Pathol 2007, 171: 14–18. 10.2353/ajpath.2007.070385PubMedCentralCrossRefPubMed
9.
Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57: 4593–4599.PubMed
10.
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362: 841–844. 10.1038/362841a0CrossRefPubMed
11.
Borgström P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N: Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998, 35: 1–10. 10.1002/(SICI)1097-0045(19980401)35:1<1::AID-PROS1>3.0.CO;2-OCrossRefPubMed
12.
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21: 1804–1809. 10.1093/annonc/mdq020PubMedCentralCrossRefPubMed
13.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355: 2542–2550. 10.1056/NEJMoa061884CrossRefPubMed
14.
Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJWD, Visser GWM, Zijlstra JM, Huijgens PC, van Dongen GAMS: Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 2006, 33: 1337–1345. 10.1007/s00259-006-0160-0CrossRefPubMed
15.
Rizvi SNF, Visser OJ, Vosjan MJWD, van Lingen A, Hoekstra OS, Zijlstra JM, Huijgens PC, van Dongen GAMS, Lubberink M: Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging 2012, 39: 512–520. 10.1007/s00259-011-2008-5PubMedCentralCrossRefPubMed
16.
Deri MA, Zeglis BM, Francesconi LC, Lewis JS: PET imaging with 89Zr: from radiochemistry to the clinic. Nucl Med Biol 2013, 40: 3–14. 10.1016/j.nucmedbio.2012.08.004PubMedCentralCrossRefPubMed
17.
Börjesson PKE, Jauw YWS, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GAMS, Boellaard R: Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 2009, 50: 1828–1836. 10.2967/jnumed.109.065862CrossRefPubMed
18.
Verel I, Visser GWM, Boerman OC, van Eerd JEM, Finn R, Boellaard R, Vosjan MJWD, Stigter-van Walsum M, Snow GB, van Dongen GAMS: Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003, 18: 655–661. 10.1089/108497803322287745CrossRefPubMed
19.
Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN: In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007, 48: 1313–1319. 10.2967/jnumed.107.041301CrossRefPubMed
20.
Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG: Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87: 586–592. 10.1038/clpt.2010.12CrossRefPubMed
21.
Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS: Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007, 48: 471–480.PubMed
22.
Makris NE, Boellaard R, Visser EP, de Jong JR, Vanderlinden B, Wierts R, van der Veen BJ, Greuter HJNM, Vugts DJ, van Dongen GAMS, Lammertsma AA, Huisman MC: Multicenter harmonization of 89Zr PET/CT performance. J Nucl Med 2014, 55: 264–267. 10.2967/jnumed.113.130112CrossRefPubMed
23.
van Dongen GAMS, Visser GWM, Lub-de Hooge MN, de Vries EG, Perk LR: Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007, 12: 1379–1389. 10.1634/theoncologist.12-12-1379CrossRefPubMed
24.
Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GAMS, Lub-de Hooge MN, Schröder CP, de Vries EGE: 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010, 51: 761–767. 10.2967/jnumed.109.071043CrossRefPubMed
25.
van der Bilt ARM, van Scheltinga AGTT, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JGW, van der Zee AGJ, Lub-de Hooge MN, de Jong S, de Vries EGE, Reyners AKL: Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res 2012, 18: 6306–6314. 10.1158/1078-0432.CCR-12-0406CrossRefPubMed
26.
Gaykema SBM, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen SB, de Jong JR, Bart J, de Vries J, Jansen L, de Vries EGE, Schröder CP: 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med 2013, 54: 1014–1018. 10.2967/jnumed.112.117218CrossRefPubMed
27.
Maru D, Venook AP, Ellis LM: Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res 2013, 19: 2824–2827. 10.1158/1078-0432.CCR-12-3409CrossRefPubMed
28.
van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA, Smit EF: Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012, 21: 82–91. 10.1016/j.ccr.2011.11.023CrossRefPubMed
Metadata
Title
Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer
Authors
Idris Bahce
Marc C Huisman
Eline E Verwer
Rogier Ooijevaar
Firdaouss Boutkourt
Danielle J Vugts
Guus AMS van Dongen
Ronald Boellaard
Egbert F Smit
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2014
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-014-0035-5

Other articles of this Issue 1/2014

EJNMMI Research 1/2014 Go to the issue

Original research

Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT

Original research

18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair

Original research

A pilot study of 4′-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer

Original research

Optimising the radiolabelling properties of technetium tricarbonyl and His-tagged proteins

Preliminary research

Negative contrast Cerenkov luminescence imaging of blood vessels in a tumor mouse model using [68Ga]gallium chloride

Preliminary research

The effect of volume of interest definition on quantification of lymph node immune response to a monkeypox virus infection assessed by 18F-FDG-PET